多发性骨髓瘤中肿瘤相关巨噬细胞浸润及其临床意义
研究纳入2015年8月至2017年6月70例多发性骨髓瘤患者和20例良性血液病对照,检测骨髓CD163、CD34、VEGF、Treg比例及IL-10水平。结果显示MM患者TAM浸润密度等指标均高于对照,且与血管生成、免疫抑制指标正相关,有效组治疗后TAM密度较治疗前明显下降。
要点
- MM患者骨髓TAM浸润密度、MVD、VEGF、Treg比例及IL-10水平均高于良性血液病对照(P<0.05)。
- 初诊MM有效组治疗后TAM密度较治疗前明显下降[(20.20±7.66)对(28.87±11.97)个/高倍,P=0.025]。
- TAM浸润密度与MVD、VEGF、Treg比例及IL-10水平呈正相关(P值均<0.001)。
核心结论
- 骨髓微环境中浸润的TAM与MM发生、发展、疗效及治疗耐药有关,其作用机制可能与TAM促进肿瘤血管形成及抑制免疫反应有关。
研究设计与样本
- 以2015年8月至2017年6月就诊的70例MM患者为观察对象,以20例良性血液病(缺铁性贫血13例,巨幼细胞性贫血7例)患者为对照。
- 采用免疫组化法检测骨髓标本中CD163、CD34、VEGF的表达,流式细胞术检测Treg细胞比例,ELISA法检测IL-10水平,并结合临床特征进行分析。
主要发现
- 70例MM患者中男31例、女39例,中位年龄65(50~78)岁。
- MM患者组TAM浸润密度、MVD、VEGF表达水平、Treg细胞比例及IL-10水平均较对照组升高(P值均<0.05)。
- 疾病稳定组(15例)上述指标均较初诊组(35例)和复发难治组(20例)低(P值均<0.05);初诊组与复发难治组差异无统计学意义(P值均>0.05)。
- 35例初诊MM患者中27例完成4个疗程治疗,有效组(15例)治疗后TAM浸润密度较治疗前明显下降[(20.20±7.66)对(28.87±11.97)个/高倍,t=2.362,P=0.025];无效组(12例)治疗前后差异无统计学意义[(42.00±13.76)对(48.25±13.59)个/高倍,t=1.119,P=0.275]。
- 硼替佐米方案治疗有效组(21例次)TAM浸润密度较非硼替佐米方案治疗有效组(18例次)减低[(16.52±4.26)对(19.27±5.82)个/高倍,t=1.662,P=0.170]。
关键数值与推荐
- MM患者组TAM浸润密度、MVD、VEGF表达水平、Treg细胞比例及IL-10水平均较对照组升高(P值均<0.05)。
- 疾病稳定组上述指标较初诊组和复发难治组低(P值均<0.05);初诊组与复发难治组差异无统计学意义(P值均>0.05)。
- 有效组治疗后TAM浸润密度较治疗前明显下降[(20.20±7.66)对(28.87±11.97)个/高倍,t=2.362,P=0.025];无效组治疗前后差异无统计学意义[(42.00±13.76)对(48.25±13.59)个/高倍,t=1.119,P=0.275]。
- 硼替佐米方案治疗有效组(21例次)TAM浸润密度较非硼替佐米方案治疗有效组(18例次)减低[(16.52±4.26)对(19.27±5.82)个/高倍,t=1.662,P=0.170]。
- TAM浸润密度与MVD、VEGF表达水平、Treg细胞比例及IL-10水平呈正相关(P值均<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical significance of tumor associated macrophages (TAM) in multiple myeloma (MM) and the relationship with angiogenesis and immunosuppression. Methods: Seventy cases of MM patients diagnosed from August 2015 to June 2017 were enrolled in the study as experimental group, 20 cases of benign hematological diseases (13 with iron deficiency anemia and 7 with megaloblastic anemia) patients as control group. Immunohistochemical method was used to detect the expression of CD163, CD34 and VEGF in bone marrow samples, and flow cytometry was used to detect the proportion of regulatory T cell (Treg cells), ELISA was used to detect the level of IL-10, and the clinical features were analyzed. Results: ①Among the 70 patients, there were 31 males and 39 females with a median age of 65 (50~78) years old. TAM infiltration density, microvascular density (MVD), VEGF expression level, Treg ratio and IL-10 level in bone marrow samples of 70 MM patients were significantly higher than those of benign hematological diseases (P<0.05). ②In the MM group, the above indexes of the patients with disease stabilized (15 cases) were lower than those of the newly diagnosed group (35 cases) and the relapse refractory group (20 cases) (P<0.05), those of relapse refractory group were higher than those of newly diagnosed group (P>0.05). ③Of the 35 newly diagnosed MM patients, 27 completed 4 courses of treatment. In the effective group (15 cases), the TAM infiltration density after treatment was significantly lower than that before treatment, the difference was statistically significant[(20.20±7.66) vs (28.87±11.97), t=2.362, P=0.025]; while in the ineffective group of 12 cases, the difference of the TAM infiltration density before and after treatment was not statistically significant[(42.00±13.76) vs (48.25±13.59), t=1.119, P=0.275]. ④TAM infiltration density in the effective group after bortezomib treatment (21 cases) were lower than those in the non-bortezomib treatment group (18 cases)[(16.52 ±4.26) vs (19.27 ±5.82), t=1.662, P=0.170]. ⑤The TAM infiltration density in MM patients was positively correlated with MVD, VEGF expression level, Treg cell ratio and IL-10 level (P<0.001). Conclusion: The infiltration of TAM in the microenvironment of MM, which may promoting angiogenesis and inhibiting immune response, is related to the occurrence, development, therapeutic effect and drug resistance of MM. 目的: 探讨肿瘤相关性巨噬细胞(TAM)在多发性骨髓瘤(MM)中的临床意义及其与肿瘤血管生成、免疫抑制的关系。 方法: 以2015年8月至2017年6月就诊的70例MM患者为观察对象,以20例良性血液病(缺铁性贫血13例,巨幼细胞性贫血7例)患者为对照,采用免疫组化法检测骨髓标本中CD163、CD34、VEGF的表达,采用流式细胞术检测Treg细胞比例,采用ELISA法检测IL-10水平,结合临床特征进行分析。 结果: ①70例患者中,男31例,女39例,中位年龄65(50~78)岁。MM患者组的TAM浸润密度、微血管密度(MVD)、VEGF表达水平、Treg细胞比例及IL-10水平均较对照组升高(P值均<0.05)。②在MM患者组中,疾病稳定组(15例)患者的上述指标均较初诊组(35例)和复发难治组(20例)低(P值均<0.05);后两组差异无统计学意义(P值均>0.05)。③35例初诊MM患者中27例完成4个疗程治疗,有效组(15例)治疗后TAM浸润密度较治疗前明显下降,差异有统计学意义[(20.20±7.66)对(28.87±11.97)个/高倍,t=2.362,P=0.025];无效组(12例)治疗前后差异无统计学意义[(42.00±13.76)对(48.25±13.59)个/高倍,t=1.119,P=0.275]。④硼替佐米方案治疗有效组患者(21例次)的TAM浸润密度较非硼替佐米方案治疗有效组(18例次)减低[(16.52 ±4.26)对(19.27±5.82)个/高倍,t=1.662,P=0.170]。⑤MM患者的TAM浸润密度与MVD、VEGF表达水平、Treg细胞比例及IL-10水平呈正相关(P值均<0.001)。 结论: 骨髓微环境中浸润的TAM与MM发生、发展、疗效及治疗耐药有关,其作用机制可能与TAM促进肿瘤血管形成及抑制免疫反应有关。.
引用
- Gui QL, Wang YS, Huang S, et al. [Infiltration of tumor associated macrophages in multiple myeloma and its clinical significance]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562446. doi:10.3760/cma.j.issn.0253-2727.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。